Post-Operative Nausea And Vomiting Study In Female Patients
NCT ID: NCT00274690
Last Updated: 2017-01-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
435 participants
INTERVENTIONAL
2005-02-28
2005-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of the Effect of Ondansetron and Combined Ondansetron and Betahistine on Postoperative Nausea and Vomiting After Gynecological Laparoscopy
NCT02026778
Effects of Ondansetron, Metoclopramide and Granisetron on Perioperative Nausea and Vomiting in Patients Undergone Bariatric Surgery
NCT05087615
Dimenydrinate vs Ondansetron for PONV (DONV)
NCT05590936
Intravenous Versus Intraperitoneal Instillation of Ondansetron for Decreasing Incidence of Nausea and Vomiting After Laparoscopic Gynecological Surgeries.
NCT05317611
Drug and Dose Adjustment in Preventing Postoperative Nausea and Vomiting
NCT04719741
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GW679769
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Undergoing gynecologic or gallbladder surgery.
Exclusion Criteria
* post-menopausal
18 Years
55 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
San Francisco, California, United States
GSK Investigational Site
Melbourne, Florida, United States
GSK Investigational Site
West Palm Beach, Florida, United States
GSK Investigational Site
Chicago, Illinois, United States
GSK Investigational Site
Grand Rapids, Michigan, United States
GSK Investigational Site
Royal Oak, Michigan, United States
GSK Investigational Site
Camden, New Jersey, United States
GSK Investigational Site
Winston-Salem, North Carolina, United States
GSK Investigational Site
Dallas, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
Seattle, Washington, United States
GSK Investigational Site
Copenhagen, , Denmark
GSK Investigational Site
Glostrup Municipality, , Denmark
GSK Investigational Site
Viborg, , Denmark
GSK Investigational Site
Lai Chi Kok, , Hong Kong
GSK Investigational Site
Pokfulam, , Hong Kong
GSK Investigational Site
Shamshuipo, Kowloon, , Hong Kong
GSK Investigational Site
Shatin, New Territories, , Hong Kong
GSK Investigational Site
Tuenmen, , Hong Kong
GSK Investigational Site
Budapest, , Hungary
GSK Investigational Site
Budapest, , Hungary
GSK Investigational Site
Szentes, , Hungary
GSK Investigational Site
Kfar Saba, , Israel
GSK Investigational Site
Tel Litwinsky, , Israel
GSK Investigational Site
Gjettum, , Norway
GSK Investigational Site
Oslo, , Norway
GSK Investigational Site
Skien, , Norway
GSK Investigational Site
Manila, , Philippines
GSK Investigational Site
Manila, , Philippines
GSK Investigational Site
Ljubljana, , Slovenia
GSK Investigational Site
Novo Mesto, , Slovenia
GSK Investigational Site
Slovenj Gradec, , Slovenia
GSK Investigational Site
Badalona(Barcelona), , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Pamplona, , Spain
GSK Investigational Site
Bangkok, , Thailand
GSK Investigational Site
Bangkok, , Thailand
GSK Investigational Site
Glasgow, Lanarkshire, United Kingdom
GSK Investigational Site
Glasgow, Lanarkshire, United Kingdom
GSK Investigational Site
Glasgow, Lanarkshire, United Kingdom
GSK Investigational Site
Edinburgh, Midlothian, United Kingdom
GSK Investigational Site
Livingston, West Lothian, United Kingdom
GSK Investigational Site
Hull, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NKT102245
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.